关键词:

血液透析, 地黄叶总苷胶囊, 左卡尼汀, 炎症因子, 残余肾功能, 氧化应激

Abstract:

Objective　To explore the effects of Rehmannia leaf glycoside capsules combined with L-carnitine on inflammatory factors, residual renal function (RRF), and oxidative stress in hemodialysis patients. Methods　A total of 124 patients with chronic renal failure who received hemodialysis treatment in the People's Hospital of Xiangxiang from January 2020 to December 2022 were prospectively selected in this study and were divided into a control group and a combination group by the random number table method, with 62 cases in each group. The control group included 35 males and 27 females, aged (49.29±5.43) years; the combination group included 37 males and 25 females, aged (49.58±5.46) years. The control group received L-carnitine treatment, and the combination group received Rehmannia leaf glycoside capsules + L-carnitine treatment, continuous treatment for 2 months. The inflammatory factors [hypersensitive C-reactive protein (hs-CRP), interleukin-2 (IL-2), and tumor necrosis factor-α (TNF-α)], renal function indexes [serum creatinine, urea nitrogen, and RRF], and oxidative stress indexes [malondialdehyde (MDA), reactive oxygen species (ROS), and advanced oxidation protein products (AOPP)] before treatment and 2 months after treatment and adverse reactions were compared between the two groups. t test and χ² test were used. Results　After 2 months of treatment, the levels of inflammatory factors in both groups were decreased compared with those before treatment (all P<0.05), and the levels of hs-CRP [(4.03±1.13) mg/L], IL-2 [(8.26±1.34) ng/L], and TNF-α [(31.46±4.53) ng/L] in the combination group were lower than those in the control group [(7.05±1.59) mg/L, (11.05±2.02) ng/L, and (44.29±5.24) ng/L], with statistically significant differences (t=12.191, 9.063, and 14.585; all P<0.05). After 2 months of treatment, the levels of renal function indexes in both groups were decreased compared with those before treatment (all P<0.05), the levels of serum creatinine [(464.33±21.16) μmol/L] and urea nitrogen [(15.58±2.46) mmol/L] in the combination group were lower than those in the control group [(514.26±28.25) μmol/L and (19.27±3.15) mmol/L], and the level of RRF [(4.29±1.13) ml/min] was higher than that in the control group [(2.54±0.76) ml/min], with statistically significant differences (t=17.162, 7.270, and 10.119; all P<0.05). After 2 months of treatment, the levels of oxidative stress indexes in both groups were decreased compared with those before treatment (all P<0.05), and the levels of MDA [(5.02±1.13) nmol/L], ROS [(192.35±17.59) μmol/L], and AOPP [(89.45±9.58) μmol/L] in the combination group were lower than those in the control group [(8.15±2.10) nmol/L, (264.16±21.47) μmol/L, and (112.04±12.67) μmol/L], with statistically significant differences (t=10.335, 20.372, and 11.198; all P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the combination group and the control group [8.06% (5/62) vs. 11.29% (7/62)] (χ²=0.369, P=0.544). Conclusion　Rehmannia leaf glycoside capsules combined with L-carnitine has definite efficacy in the treatment of hemodialysis patients, which can reduce the production of inflammatory factors, relieve the oxidative stress, and protect the RRF, and has good safety and clinical application value.

Key words:

Hemodialysis, Rehmannia leaf glycoside capsules, L-carnitine, Inflammatory factors, Residual renal function, Oxidative stress